LA JOLLA LJP 394 IND FILING FOR LUPUS SLATED FOR SECOND HALF OF 1994
Executive Summary
LA JOLLA LJP 394 IND FILING FOR LUPUS SLATED FOR SECOND HALF OF 1994, the San Diego biotech company said in a May 24 prospectus for an initial public offering. LJP 394, La Jolla Pharmaceutical's lead compound, is a product of the company's Tolerance Technology, which is designed to treat auto-immune diseases.